Hematopoietic Cell Transplantation for Solid Tumors of Childhood

Effective: January 1, 2019

Next Review: August 2019
Last Review: December 2018

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Transplantation is performed to restore bone marrow function following bone-marrow-toxic doses of chemotherapy.

MEDICAL POLICY CRITERIA

Notes:
- See Appendix I for a glossary of terms.
- This policy addresses only solid tumors of childhood. Solid tumors in adults are considered separately in Transplant, Policy No. 45.27. This policy also does not address hematopoietic cell transplantation (HCT) as a treatment of embryonal tumors arising in the central nervous system (cerebral neuroblastoma), tumors derived from glial cells (i.e., astrocytoma, oligodendroglioma, or glioblastoma multiforme), or germ cell tumors which are considered separately in Transplant, Policy Numbers 45.33, 45.34, and 45.38, respectively.

I. Autologous hemopoietic cell transplantation may be considered medically necessary for any of the following indications (A.-C.):
A. Ewing’s sarcoma when either of the following are met:
   1. For initial treatment of high-risk Ewing’s sarcoma. Patients may be categorized as “high-risk” if any of the following are present: metastatic disease, unfavorable tumor location (e.g., patients with pelvic primaries have worse outcomes), larger tumor size, or older age of the patient.
   2. To consolidate remissions or as a salvage therapy for those with residual, recurrent or refractory Ewing’s sarcoma.

B. Neuroblastoma when either of the following are met:
   1. For initial treatment of high-risk neuroblastoma. Patients may be characterized as high-risk if any of the following are present: age older than 1 year, disseminated disease, MYCN oncogene amplification, or unfavorable histopathologic findings.
   2. Recurrent or refractory neuroblastoma.

C. Wilms tumor, recurrent, high-risk

D. Metastatic retinoblastoma

II. Tandem autologous hematopoietic cell transplantation may be considered medically necessary for high-risk neuroblastoma characterized by any of the following: age older than 1 year, disseminated disease, MYCN oncogene amplification, or unfavorable histopathologic findings.

III. The following are considered investigational:

   A. Autologous hemopoietic cell transplantation for the following indications: Initial treatment of low- or intermediate-risk Ewing’s sarcoma; initial treatment of low- or intermediate-risk neuroblastoma; other solid tumors of childhood, including but not limited to the following: a) Osteosarcoma, b) Retinoblastoma without metastasis, c) Rhabdomyosarcoma, d) Wilms tumor, other than recurrent, high-risk.

   B. Tandem or multiple hematopoietic cell transplantation for the treatment of all other types of pediatric solid tumors except high-risk neuroblastoma (criterion II.)

   C. Allogeneic (myeloablative or nonmyeloablative) hematopoietic cell transplantation for treatment of all pediatric solid tumors.

   D. Salvage allogeneic hematopoietic cell transplantation for all pediatric solid tumors that relapse after autologous transplant or fail to respond.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

POLICY GUIDELINES

SUBMISSION OF DOCUMENTATION

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.
• History and physical/chart notes
• Ewing’s Sarcoma, neuroblastoma, or Wilms tumor: Indicate if high-risk
• Ewing’s Sarcoma: Indicate if request is to consolidate remissions or as a salvage therapy for those with residual, recurrent or refractory Ewing's sarcoma
• Neuroblastoma: Indicate if request is for recurrent or refractory neuroblastoma
• Tandem autologous hematopoietic cell transplantation for high-risk neuroblastoma, indicate if any of the following are present:
  o age older than 1 year,
  o disseminated disease,
  o MYCN oncogene amplification,
  o or unfavorable histopathologic findings.

CROSS REFERENCES
1. Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Cell Transplant, Transplant, Policy No. 45.03
2. Placental and Umbilical Cord Blood as a Source of Stem Cells, Transplant, Policy No. 45.16
3. Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults, Transplant, Policy No. 45.27
4. Hematopoietic Cell Transplantation for CNS Embryonal Tumors and Ependymoma, Transplant, Policy No. 45.33
5. Autologous Hematopoietic Cell Transplantation for Malignant Astrocytomas and Gliomas, Transplant, Policy No. 45.34
6. Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors, Transplant, Policy No. 45.38

BACKGROUND

HEMATOPOIETIC CELL TRANSPLANTATION FOR SOLID TUMORS

Hematopoietic cell transplantation (HCT, previously referred to in this policy as a hematopoietic stem cell transplant [HSCT]) refers to a procedure in which hematopoietic cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiation therapy. Hematopoietic cells may be obtained from the transplant recipient (autologous HCT) or can be harvested from a donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD).

Autologous HCT takes advantage of the steep dose-response relationship observed with many chemotherapeutic agents and allows for escalation of chemotherapy doses above those limited by myeloablation. The use of allogeneic HCT for solid tumors relies on a graft-versus-tumor effect. Allogeneic HCT is uncommonly used in solid tumors, and may be used if an autologous source cannot be cleared of tumor or cannot be harvested.

SOLID TUMORS OF CHILDHOOD

Solid tumors of childhood are defined as those not arising from myeloid or lymphoid cells. Some of the most common solid tumors of childhood are neuroblastoma, Ewing’s sarcoma/Ewing's Sarcoma Family of Tumors, Wilms tumor, rhabdomyosarcoma, osteosarcoma, and retinoblastoma.
The prognosis for pediatric solid tumors has improved over the last two decades, mostly due to the application of multiagent chemotherapy and improvements in local control therapy (including aggressive surgery and advancements in radiation therapy). However, patients with metastatic, refractory, or recurrent disease continue to have poor prognoses, and these “high-risk” patients are candidates for more aggressive therapy, including autologous HCT, in an effort to improve event-free survival (EFS) and overall survival (OS).

Descriptions of the solid tumors of childhood that are addressed in this policy are as follows:

**PERIPHERAL NEUROBLASTOMA**

Note: Cerebral neuroblastoma is considered separately in Transplant No. 45.33 related to embryonal tumors.

Neuroblastoma is the most common extracranial solid tumor of childhood, with 90% of cases presenting in children ages 5 or younger. These tumors originate where sympathetic nervous system tissue is present, within the adrenal medulla or paraspinal sympathetic ganglia. They are remarkable for their broad spectrum of clinical behavior, with some undergoing spontaneous regression, others differentiating into benign tumors, and still others progressing rapidly and resulting in patient death.

Patients with neuroblastoma are stratified into prognostic risk groups (low, intermediate, and high) that determine treatment plans. Risk variables include age at diagnosis, clinical stage of disease, tumor histology, and certain molecular characteristics, including the presence of the MYCN oncogene. Tumor histology is categorized as favorable or unfavorable, according to the degree of tumor differentiation, proportion of tumor stromal component, and index of cellular proliferation. It is well established that MYCN amplification is associated with rapid tumor progression and a poor prognosis, even in the setting of other coexisting favorable factors. Loss of heterozygosity (LOH) at chromosome arms 1p and 11q occurs frequently in neuroblastoma. Although 1p LOH is associated with MYCN amplification, 11q is usually found in tumors without this abnormality. Some recent studies have shown that 1p LOH and unbalanced 11q LOH are strongly associated with outcome in patients with neuroblastoma, and both are independently predictive of worse progression-free survival (PFS) in patients with low- and intermediate-risk disease. Although the use of these LOH markers in assigning treatment in patients is evolving, they may prove useful to stratify treatment.

Clinical stage of disease is based on the International Neuroblastoma Staging System (INSS) as follows:

- **Stage 1**
  
  Localized tumor with complete gross excision, with or without microscopic residual disease; lymph nodes negative for tumor.

- **Stage 2A**
  
  Localized tumor with incomplete gross excision; lymph nodes negative for tumor.

- **Stage 2B**
  
  Localized tumor with or without complete gross excision, with ipsilateral lymph nodes
positive for tumor.

- **Stage 3**

  Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration or by lymph node involvement.

- **Stage 4**

  Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs, except as defined for stage 4S.

- **Stage 4S**

  Localized primary tumor as defined for stage 1, 2A, or 2B, with dissemination limited to skin, liver, and/or bone marrow (marrow involvement less than 10%), limited to children younger than 1 year of age.

The low-risk group includes patients younger than 1 year of age with stage 1, 2, or 4S with favorable histopathologic findings and no MYCN oncogene amplification. High-risk neuroblastoma is characterized by an age older than 1 year, disseminated disease, MYCN oncogene amplification, and unfavorable histopathologic findings.

In general, most patients with low-stage disease have excellent outcomes with minimal therapy, and with INSS stage 1 disease, most patients can be treated by surgery alone.\(^2\) Most infants, even with disseminated disease, have favorable outcomes with chemotherapy and surgery.\(^2\) In contrast, most children older than 1 year with advanced-stage disease die due to progressive disease, despite intensive multimodality therapy\(^2\), and relapse remains common. Treatment of recurrent disease is determined by the risk group at the time of diagnosis, and the extent of disease and age of the patient at recurrence.

**EWING’S SARCOMA AND THE EWING FAMILY OF TUMORS**

Ewing’s sarcoma family of tumors (ESFT) encompasses a group of tumors that have in common some degree of neuroglial differentiation and a characteristic underlying molecular pathogenesis (chromosomal translocation). The translocation usually involves chromosome 22 and results in fusion of the EWS gene with one of the members of the ETS (E-twenty-six) family of transcription factors, either FLI1 (90–95%) or ERG (5–10%). These fusion products function as oncogenic aberrant transcription factors. Detection of these fusions is considered to be specific for the ESFT, and helps further validate the diagnosis. Included in ESFT are “classic” Ewing’s sarcoma of bone, extrasosseous Ewing’s, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumors (chest wall).

Most commonly diagnosed in adolescence, ESFT can be found in bone (most commonly) or soft tissue; however, the spectrum of ESFT has also been described in various organ systems. Ewing’s is the second most common primary malignant bone tumor. The most common primary sites are the pelvic bones, the long bones of the lower extremities, and the bones of the chest wall.
Current therapy for Ewing’s sarcoma favors induction chemotherapy, with local control consisting of surgery and/or radiation (dependent on tumor size and location), followed by adjuvant chemotherapy. Multiagent chemotherapy, surgery, and radiation therapy have improved the PFS in patients with localized disease to 60%–70%.[7] The presence of metastatic disease is the most unfavorable prognostic feature, and the outcome for patients presenting with metastatic disease is poor, with 20%–30% PFS. Other adverse prognostic factors that may categorize a patient as having “high-risk” Ewing’s are tumor location (e.g., patients with pelvic primaries have worse outcomes), larger tumor size, or older age of the patient. However, “high-risk” Ewing’s has not always been consistently defined in the literature.

Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood, shows skeletal muscle differentiation. The most common primary sites are the head and neck (e.g., parameningeal, orbital, pharyngeal), genitourinary tract, and extremities.[8] Most children with RMS present with localized disease, and with conventional multimodal therapy, the cure rate in this group is 70%–80%.[9] However, approximately 15% of children present with metastatic disease, and despite the introduction of new drugs and intensified treatment, the 5-year survival is 20%–30% for this “high-risk” group.[8,10]

Wilms tumor, the most common primary malignant renal tumor of childhood, is highly sensitive to chemotherapy and radiation, and current cure rates exceed 85%.[11] Ten to 15% of patients with favorable histology and 50% of patients with anaplastic tumors experience tumor progression or relapse.[11] Similar to newly diagnosed Wilms tumor, relapsed Wilms tumor is a heterogeneous disease, and current treatment strategies stratify intensity and scheduling of the treatment modalities based on prognostic features. For newly diagnosed disease, the most important prognostic features are stage and histology. Similar risk-adapted strategies are being attempted for the 15% of patients who experience relapse. Success rates after relapse range from 25%–45%. For patients with adverse prognostic factors (histologically anaplastic tumors, relapse less than 6–12 months after nephrectomy, second or subsequent relapse, relapse within the radiation field, bone or brain metastases) event-free survival is less than 15%.[12] However, recent trials with HDC and autologous HCT have reported 3- or 4-year OS rates from 60%–73%.[13]

Osteosarcoma is a primary malignant bone tumor that is characterized by formation of bone or osteoid by the tumor cells. Osteosarcoma occurs predominantly in the appendicular skeleton of adolescents. In children and adolescents, more than 50% of these tumors arise from bones around the knee. The prognosis of localized osteosarcoma has greatly improved over the last 30 years with OS rates increasing from 10% with surgery alone (usually amputation) to 70% with the introduction of neoadjuvant chemotherapy and limb-sparing surgery.[14] However, 30%–40% of patients with non-metastatic osteosarcoma of the extremities experience recurrent disease, most commonly in the lungs.[14] Mean 5-year post-relapse survival rate is approximately 28%, with some groups having a 0% OS rate. Prognostic factors for recurrence include site and size of the primary tumor, presence of metastases at the time of diagnosis, resection adequacy, and tumor response to preoperative chemotherapy (measured as percent of tumor necrosis in the resection specimen). Overall EFS for patients with metastatic disease at diagnosis is about 20%–30%.[15]
RETINOBLASTOMA

Retinoblastoma is the most common primary tumor of the eye in children. It may occur as a heritable (25% to 30%) or nonheritable (70% to 75%) tumor.[16] Cases may be unilateral or bilateral, with bilateral tumors almost always occurring in the heritable type. The type of treatment depends on the extent of disease. Retinoblastoma is usually confined to the eye, and with current therapy, has a high cure rate. However, once disease has spread beyond the eye, survival rates drop significantly; 5-year disease-free survival is reported to be less than 10% in those with extraocular disease, and stage 4B disease (i.e., disease metastatic to the CNS) has been lethal in virtually all cases reported.[17]

The strategy for nonmetastatic disease depends on the disease extent, but may include focal therapies (e.g., laser photocoagulation, cryotherapy, plaque radiotherapy), intravitreal chemotherapy, intra-arterial chemotherapy, systemic chemotherapy, enucleation, or a combination.[18] For metastatic disease, intensive multimodal therapy with high-dose chemotherapy, with or without radiotherapy, is standard care.

EVIDENCE SUMMARY

The principal outcomes associated with treatment of pediatric solid tumors are typically measured in units of survival past treatment: event-free survival (EFS), a period of time following treatment where the disease is undetectable; progression-free survival (PFS), the duration of time after treatment before the advancement or progression of disease; and overall survival (OS), the period of time the patient remains alive following treatment. Risk of graft-versus-host disease is another primary outcome among patients undergoing allogeneic hematopoietic cell transplantation (HCT). Ideally, in order to understand the impact of HCT for treatment of peripheral neuroblastoma, Ewing’s sarcoma, or any other solid childhood malignancy, clinical trials that compare this therapy with standard medical treatment (chemotherapy, and/or surgical resection with or without radiation), are needed. Further, for treatment of malignant solid tumors, particularly those with a poor prognosis, an understanding of any adverse treatment effects must be carefully weighed against any benefits associated with treatment to understand the net treatment effect.

PERIPHERAL NEUROBLASTOMA

Single Autologous Hematopoietic Cell Transplantation (HCT)

Systematic Review

In 2013, Yalcin published a Cochrane meta-analysis on the three well-designed, randomized controlled trials (RCTs)[19-22] using autologous hematopoietic cell transplantation (HCT) in the treatment of 739 children with high-risk neuroblastoma.[23] The primary objective was to compare the efficacy of myeloablative therapy with conventional therapy. The included studies all used an age of 1 year as the cut-off point for pretreatment risk stratification. There was a statistically significant difference in EFS in favor of myeloablative therapy over conventional chemotherapy or no further treatment (three studies, 739 patients; hazard ratio [HR]=0.78, 95% CI, 0.67 to 0.90). There was a statistically significant difference in OS in favor of myeloablative therapy over conventional chemotherapy or no further treatment (two studies, 360 patients; HR=0.74, 95% CI, 0.57 to 0.98). However, when additional follow-up data were included in the analyses, the difference in EFS remained statistically significant (3 studies, 739 patients; HR=0.79, 95% CI, 0.70 to 0.90), but the difference in OS was no longer statistically
significant (2 studies, 360 patients; HR=0.86, 95% CI, 0.73 to 1.01). The meta-analysis of secondary malignant disease and treatment-related death did not show any statistically significant differences between the treatment groups. Data from one study (379 patients) showed a significantly higher incidence of renal effects, interstitial pneumonitis, and veno-occlusive disease in the myeloablative group compared with conventional chemotherapy, whereas for serious infections and sepsis, no significant difference between the treatment groups was identified. No information on quality of life was reported.

Available evidence on the use of autologous HCT in high-risk neuroblastoma is sufficient to suggest treatment benefit with transplant.

**Tandem Hematopoietic Cell Transplantation (HCT)**

**Systematic Review**

A comparative effectiveness review was conducted on the use of hematopoietic cell transplantation in the pediatric population by the Blue Cross and Blue Shield Association Technology Evaluation Center for the Agency for Healthcare Research and Quality (AHRQ).[24] The review concluded that the body of evidence on overall survival with tandem HCT compared to single HCT for the treatment of high-risk neuroblastoma was insufficient to draw conclusions.

**Nonrandomized Studies**

Sung retrospectively analyzed the efficacy of single versus tandem autologous HCT in patients older than 1 year of age newly diagnosed with stage 4 neuroblastoma from 2000 to 2005 who were enrolled in the Korean Society of Pediatric Hematology-Oncology registry.[25] Patients were assigned to receive a single (n=70) or tandem (n=71) autologous HCT at diagnosis; 57 and 59 patients underwent single and tandem transplantation as scheduled, respectively. Patient characteristics between the 2 groups were similar with the exception of a higher proportion of patients in the tandem group having bone metastases. Median follow-up was 56 months (range 24-88 months) from diagnosis. Transplant-related mortality occurred in 9 patients in the single transplant group and in 8 in the tandem group (2 after the first transplant and 6 after the second). The intent-to-treat survival rate was 5-year EFS for single versus tandem 31.3% +/- 11.5% and 51.2% +/- 12.4%, respectively; p=0.03. When the survival analysis was confined to the patients who proceeded to transplant, the probability of relapse-free survival (RFS) after the first transplant was higher in the tandem group than the single group with borderline significance (59.1% +/- 13.5% vs. 41.6% +/- 14.5%; p=0.099). The difference became significant when the analysis was confined to patients who did not achieve a CR prior to the first transplant (55.7% +/- 17.0% vs. 0%; p=0.012). The authors concluded that tandem HCT for high-risk neuroblastoma is superior to single HCT in terms of survival, particularly in patients not in CR prior to the HCT.

Ladenstein reported on 28 years of experience for more than 4,000 transplants for primary (89%) and relapsed (11%) neuroblastoma in the European Group for Blood and Marrow Transplantation registry.[26] Procedures included single autologous (n=2,895), tandem autologous (n=455) and allogeneic HCT (n=71). The median age at the time of transplantation was 3.9 years (range 0.3-62 years), with 77 patients older than 18 years. The median follow-up time from HCT was 9 years. Transplant-related mortality (TRM) decreased over time in the registry for the patients who received autologous transplants only. The cumulative incidence of TRM was 4%, 6%, and 8%, respectively, at day 100, one year, and five years for the
autologous group, and 13%, 16%, and 18%, respectively for the allogeneic group. Five-year OS for the autologous group (single and tandem) was 37% versus 25% in the allogeneic setting. Five-year OS for single versus tandem autologous HCT was 38% versus 33%, respectively (p=0.105).

Kim reported a retrospective analysis of 36 patients with high-risk (stage 3 or 4) neuroblastoma who underwent either a single autologous HCT (n=27) or a tandem autologous HCT (n=9) at Seoul National University Children’s Hospital between 1996 and 2004.[27] EFS of patients who underwent double HCT was similar to that of patients who underwent a single autologous HCT (p=0.5).

George reported long-term survival data of high-risk neuroblastoma patients (n=82) treated with tandem autologous HCT between 1994 and 2002.[28] Median age at diagnosis was 35 months (range 6 months to 18 years). Three- and five-year OS were 74% (95% CI 62-82%) and 64 % (95% CI 52-74%) respectively.

von Allmen reported outcomes on 76 patients with previously untreated high-risk stage III/IV neuroblastoma treated with aggressive surgical resection with or without local radiation therapy followed by tandem autologous high-dose chemotherapy and stem-cell rescue.[29] Overall EFS for the series at three years was 56%.

Marcus reported outcomes in 52 children with stage 4 or high-risk stage 3 neuroblastoma treated with induction chemotherapy, surgical resection of the tumor when feasible, local radiotherapy and consolidation with tandem autologous HCT.[30] Radiotherapy was given if gross or microscopic residual disease was present prior to the myeloablative cycles (n=37). Of the 52 consecutively treated patients analyzed, 44 underwent both transplants, 6 underwent a single transplant, and 2 progressed during induction. The 3-year EFS was 63%, with a median follow-up of 29.5 months.

Kletzel reported on the outcomes of 25 consecutive newly diagnosed high-risk neuroblastoma patients and one with recurrent disease, diagnosed between 1995 and 2000, and treated with triple-tandem autologous HCT.[31] After stem-cell rescue, patients were treated with radiation to the primary site. Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Seventeen patients completed all 3 cycles of high-dose therapy and stem-cell rescue, 2 patients completed 2 cycles and 3 patients completed one cycle. There was one toxic death, and one patient died from complications of treatment for graft failure. Median follow-up was 38 months, and the 3-year EFS and survival rates were 57% +/- 11% and 79% +/-10%, respectively.

Grupp reported the outcomes of a Phase II trial that involved 55 children with high-risk neuroblastoma who underwent tandem autologous HCT.[32] Five patients completed the first HCT course but did not complete the second. There were four toxic deaths. With a median follow-up of 24 months from diagnosis, three-year EFS was 59%.

Despite the low-quality of existing evidence on the use of tandem autologous HCT for treatment of high-risk neuroblastoma, there is a suggestion of potentially increased survival with tandem transplant compared with single transplant.

**Reduced Intensity Conditioning**

Sung evaluated feasibility and efficacy of reduced-intensity allogeneic cell transplantation (RI alloSCT) in six children with neuroblastoma who failed tandem HDCT/autoSCT.[33] Although
the regimen-related short-term toxicity was manageable in intensively pretreated patients, graft-versus-tumor effect was not sufficiently strong to control tumor progression in patients who had a significant tumor burden at transplant.

EWING’S SARCOMA AND THE EWING FAMILY OF TUMORS (ESFT)

During the 1980’s and 90’s, several small series, case reports, and a report from the European Bone Marrow Transplant Registry suggested that autologous HCT could improve the outcome for patients with high-risk ESFT. The original policy position on Ewing’s was based on these studies and reports. Subsequent to the publication of these reports, additional evidence has been reported on the use of autologous HCT in ESFT, including a systematic review and several non-randomized studies.

Systematic Review

The AHRQ comparative effectiveness review of HCT in the pediatric population also addressed ESFT, concluding that low-strength evidence on overall survival suggests no benefit with single autologous HCT compared with conventional therapy for the treatment of high-risk ESFT. The body of evidence on overall survival with tandem autologous HCT compared with single autologous HCT for the treatment of high-risk ESFT and overall survival is insufficient to draw conclusions.

Nonrandomized Studies

In 2015, Jahnukainen reported their single-institution experience with high-dose thiotepa as consolidation therapy with autologous HCT for high-risk Ewing family tumors. Data from 24 patients who were treated between 1986 and 2012 were retrospectively analyzed. Ewing family tumor patients received single and tandem high-dose therapy with special emphasis on HD-thiotepa as the emphasis of the regimen. The 10-year overall survival for the entire cohort was 0.73±0.01. Thirteen out of the 24 underwent high-dose therapy (10 single, 3 tandem). There was no toxic mortality.

Early case series were characterized by small numbers of patients, and comparison of the studies was difficult for several reasons. Within each report, patients often received a variety of chemotherapeutic regimens and many of the studies did not share the same patient eligibility criteria (and in some, the definition of high risk included patients with criteria that did not result in inferior prognosis). In addition, some studies used autologous, and others allogeneic HCT.

Subsequent to the early wave of publications, in 2001, Meyers reported on a prospective study with autologous HCT in 32 patients with newly diagnosed Ewing’s sarcoma metastatic to bone and/or bone marrow. Induction therapy consisted of 5 cycles of cyclophosphamide-doxorubicin-vincristine, alternating with ifosfamide-etoposide. Twenty-three patients proceeded to the consolidation phase with melphalan, etoposide, total body irradiation, and autologous HCT (of the 9 patients who did not proceed, two were secondary to toxicity and four to progressive disease). Three patients died during the high-dose phase. Two-year EFS for all eligible patients was 20% and 24% for the 29 patients who received the high-dose consolidation therapy. The study concluded that consolidation with high-dose chemotherapy (HDC), TBI, and autologous stem-cell support failed to improve the probability of EFS for this cohort of patients when compared with a similar group of patients treated with conventional therapy. The authors noted that their findings differed from some previous studies and noted that the previous studies suffered from heterogeneous patient populations. The authors
concluded that future trials of autologous HCT must be conducted prospectively, with identification of a group at high risk for failure, and all patients entering the study at the same point in therapy.

Gardner reported the results of 116 patients with Ewing’s sarcoma who underwent autologous HCT (80 as first-line therapy and 36 for recurrent disease) between 1989 and 2000. Five-year probabilities of PFS in patients who received HCT as first-line therapy were 49% (95% CI: 30–69%) for those with localized disease at diagnosis and 34% (95% CI: 22–47%) for those with metastatic disease at diagnosis. For the population with localized disease at diagnosis and recurrent disease, five-year probability of PFS was 14% (95% CI: 3–30%). The authors concluded that PFS rates after autologous HCT were comparable to rates seen in patients with similar disease characteristics treated with conventional therapy.

Results from one group of patients in the Euro-EWING 99 trial were reported by Ladenstein for patients with primary disseminated multifocal Ewing sarcoma (PDMES). From 1999 to 2005, 281 patients with PDMES were enrolled in the Euro-EWING 99 R3 study; the Euro-EWING99 Committee agreed to stop enrollment to this group and release the data. Median age was 16.2 years (range: 0.4-49 years). Patients with isolated lung metastases were not part of the analysis. The recommended treatment consisted of induction chemotherapy, HDC and autologous HCT and local treatment to the primary tumor (surgery and/or radiation or neither). Induction therapy was completed by 250 (89%) of patients. One-hundred sixty-nine (60%) of the patients proceeded to HCT; reasons for not proceeding to HCT included disease progression or other or unknown reasons. One patient died during induction therapy from sepsis. High-dose chemotherapy TRM consisted of three patients dying within the first 100 days after high-dose therapy- one from acute respiratory distress syndrome and two from severe veno-occlusive disease and septicemia; late deaths included three patients who died 1-1.5 years after high-dose therapy. After a median follow-up of 3.8 years, score allowed allocation of patients with PDMES at diagnosis to three risk groups with the following outcomes: group 1 (score ≤3; n=82) EFS of 50%, group 2 (score >3 but ≤5; n=102) EFS of 25%, and group 3 (score ≥5; n=70) EFS of 10% (p<0.0001). The authors concluded that this scoring system may facilitate risk-adapted treatment strategies. The estimated 3-year EFS and OS for all 281 patients were 27% +/- 3% and 34% +/- 4%, respectively. Individual risk factors were brought into a scoring model to predict outcome at diagnosis. The values of the score points were based on log-hazard ratios, and the factor with the smallest hazard ratio was assigned one point. One score point was attributed to the following risk factors: age older than 14 years, bone marrow metastases, one bone lesion and additional presence of lung metastases; 1.5 points were attributed to the risk factors of primary tumor volume ≥200 mL and more than one bone lesion.

RHABDOMYOSARCOMA (RMS)

Available evidence on the use of HCT in RMS consists of several systematic reviews summarizing a body of non-randomized trials.

Systematic Reviews

A 2010 Cochrane review of non-randomized studies, the effectiveness of HDC with stem cell rescue (SRC) versus standard-dose chemotherapy in improving event-free survival (EFS) and overall survival (OS) of children and young adults with metastatic rhabdomyosarcoma was assessed. The review concluded that use of HDC with SCR as a standard therapy for children with metastatic rhabdomyosarcoma is not justified at this time. Overall, the quality and
The quantity of evidence is limited as no RCTs could be identified, and available non-randomized studies have significant methodological limitations, especially selection bias. The review stated that only large, prospective RCTs could answer whether HDC with SCR improves survival in rhabdomyosarcoma.

The AHRQ comparative effectiveness review noted previously also considered the use of HCT in RMS.[24] The following conclusions were offered:

- Moderate-strength evidence on overall survival suggests no benefit with single HCT compared to conventional therapy for the treatment of high-risk metastatic rhabdomyosarcoma.
- The body of evidence on overall survival with single HCT compared to conventional therapy for the treatment of high-risk rhabdomyosarcoma of mixed tumor type is insufficient to draw conclusions.
- The body of evidence on overall survival with single HCT compared to conventional therapy for the treatment of congenital alveolar rhabdomyosarcoma, cranial parameningeal rhabdomyosarcoma with metastasis, or the use of allogeneic transplantation for metastatic rhabdomyosarcoma was insufficient to draw conclusions.

Weigel published a systematic review on 2001 on the role of autologous HCT in the treatment of metastatic or recurrent rhabdomyosarcoma, which involved a total of 389 patients from 22 studies.[39] Based on all of the data analyzing EFS and OS, they concluded that there was no significant advantage to undergoing this type of treatment.

Nonrandomized Studies

Autologous HCT has been evaluated in a limited number of patients with “high-risk” RMS (stage 4 or relapsed) in whom complete remission (CR) is achieved after standard induction therapy. Data are relatively scarce, due in part to the rarity of the condition.

Carli conducted a prospective non-randomized study of 52 patients with metastatic RMS, who were in complete remission after induction therapy and subsequently received HDC (“megatherapy”) and autologous HCT and compared them to 44 patients who were in remission after induction therapy who subsequently received conventional chemotherapy.[40] No significant differences existed between the two study groups (i.e., no differences in clinical characteristics, induction chemotherapy received, sites of primary tumor, histologic subtype, age, or presence/extent of metastases). Three-year EFS and OS were 29.7% and 40%, respectively, for the autologous HCT group and 19.2% and 27.7%, respectively, for the group that received standard consolidation chemotherapy. The difference was not statistically significant (p=0.3 and 0.2 for EFS and OS, respectively). The median time after chemotherapy to relapse was 168 days for the autologous HCT group, and 104 days for the standard chemotherapy group (p=0.05). Therefore, although there was some delay to relapse, there was no clear survival benefit from using autologous HCT compared to conventional chemotherapy.

Klingebiel prospectively compared the efficacy of two HDC treatments followed by autologous stem-cell rescue versus an oral maintenance treatment (OMT) in 96 children with stage IV soft tissue sarcoma (88 of whom had rhabdomyosarcoma).[41] Five-year OS probability for the whole group was 0.52 + 0.14 for the patients who received OMT (n=51) and 0.27 + 0.13 for the transplant group (n=45; p=0.03). For the patients with rhabdomyosarcoma, 5-year OS probability was 0.52 + 0.16 with OMT versus 0.15 + 0.12 with transplant (p=0.001). The
authors concluded that transplant has failed to improve prognosis in metastatic soft tissue sarcoma, but that OMT could be a promising alternative.

McDowell reported the results of the International Society of Paediatric Oncology (SIOP) study MMT-98, for pediatric patients from 48 centers with metastatic rhabdomyosarcoma, entered into the study from 1998 to 2005.[42] There were a total of 146 patients entered, aged 6 months to 18 years. The patients were risk-stratified and treated accordingly. One hundred and one patients were considered poor risk patients (PRG) if they were older than 10 years of age, or had bone marrow or bone metastases. Planned therapy for the PRG was induction therapy, sequential high-dose chemotherapy and peripheral blood autologous HCT and finally, maintenance therapy. Seventy-nine of the 101 PRG patients (78.2%) underwent the high-dose therapy, after which 67.1% achieved a partial or complete response. Sixty-seven of the 101 PRG patients received local treatment: 37 radiation alone, 10 surgery alone and 20 both modalities. No treatment-related deaths were reported in the PRG. Three- and five-year EFS for the PRG group was 16.5% and 14.9%, respectively and three- and five-year OS were 23.7% and 17.9%, respectively [HR=2.46; CI: 1.51-4.03; p<0.001).

WILMS TUMOR

Most studies of autologous HCT for high-risk Wilms tumor have been very small series or case reports.[11,13,43] A systematic review and meta-analysis have also been published and comprise the focus of this review.

Systematic Reviews

The AHRQ review discussed above also addressed HCT in pediatric patients with Wilms tumor, concluding: Low-strength evidence on overall survival suggests no benefit with single HCT compared to conventional therapy for the treatment of high-risk relapsed Wilms tumor.[24]

A meta-analysis reported on the efficacy of autologous HCT in recurrent Wilms' tumor for articles published between 1984 and 2008 that reported survival data.[44] Six studies were included for a total of 100 patients, and patient characteristics and treatment methods were similar across studies, although there was variation in the preparative regimens used.[11,13,43,45-47] Patients were between the ages of 11 months and 16 years, and had similar primary tumor stage, relapse location and time to relapse across studies. The four-year OS among the 100 patients was 54.1% (42.8-64.1%) and four-year EFS based on 79 patients was 50.0% (37.9-60.9%). A multivariate analysis found that site of relapse and histology were important predictors for survival, in that patients who did not have a lung-only relapse had more than three times the risk of death or recurrence than patients who relapsed in the lungs only, and the patients with unfavorable histology had more than twice the risk of death compared to those with favorable histology (hazard ratios 3.5 and 2.4, respectively). The authors compared the survival rates from these six studies in which the patients were treated with autologous HCT to patients treated with conventional chemotherapy between 1995 and 2002. The authors found that, in general, the chemotherapy treated patients had comparable or improved four-year survival compared to the HCT group, however, there was a suggestion that patients with lung-only stage 3 and 4 relapse may benefit from autologous HCT with a 21.7% survival advantage over the chemotherapy patients (however the ranges were very wide): four-year OS for the stage 3 and 4 patients with lung only relapse treated with HCT versus chemotherapy was 74.5% (51.7-87.7%) and 52.8% (29.7-71.5%), respectively.

OSTEOSARCOMA
Rare small series and case reports are available examining the use of autologous HCT in osteosarcoma.[48] Autologous HCT has been successful in inducing short-lasting remissions but has not shown an increase in survival.[14]

**RETINOBLASTOMA**

**Localized Retinoblastoma**

No studies focusing on autologous HCT for patients with localized retinoblastoma were identified.

**Metastatic Retinoblastoma**

Most studies of autologous HCT for metastatic retinoblastoma have been very small series or case reports.[49-54] In addition, one systematic review also addresses the use of autologous HCT in retinoblastoma.

**Systematic Review**

The AHRQ review considered above addressed the use of HCT in pediatric patients with retinoblastoma, concluding that available evidence on overall survival suggests no benefit with single HCT compared to conventional therapy for the treatment of extraocular retinoblastoma with central nervous system involvement.[24] The body of evidence on overall survival with single HCT compared with conventional therapy for the treatment of extraocular retinoblastoma without central nervous system (CNS) involvement was insufficient to draw conclusions. Likewise, the body of evidence on overall survival with single HCT compared with conventional therapy for the treatment of trilateral retinoblastoma without CNS involvement was also insufficient to draw conclusions.

**Nonrandomized Studies**

Dunkel reported the outcomes of 15 consecutive patients with stage 4a metastatic retinoblastoma who presented between 1993 and 2006 and were treated with HDC and autologous HCT.[55] Twelve patients had unilateral retinoblastoma and three had bilateral disease. Metastatic disease was not detected at the time of diagnosis, but became clinically evident at a median of six months (range: 1-82 months) post-enucleation. The patients had metastatic disease to bone marrow (n=14), bone (n=10), the orbit (n=9) and/or the liver (n=4). Two patients progressed prior to HCT and died. Thirteen patients underwent HCT, and 10 are retinoblastoma-free in first remission at a median follow-up of 103 months (range: 34-202 months). Three patients recurred 14-20 months post-diagnosis of metastatic disease, (two in the CNS and one in the mandible), and all died of their disease. Five-year retinoblastoma-free and event-free survival were 67% (95% CI 38-85%) and 59% (31-79%), respectively. Six of the 10 patients who survived received radiation therapy. Three patients developed secondary osteosarcoma at 4, 9 and 14 years after diagnosis of metastatic disease, two in previously irradiated fields and one in a non-irradiated field. The authors concluded that HCT was curative for the majority of patients treated in their study with stage 4a retinoblastoma.

Dunkel reported the outcomes of eight patients diagnosed with stage 4b retinoblastoma between 2000 and 2006 treated with autologous HCT.[17] Seven of the patients had leptomeningeal disease and one had only direct extension to the CNS via the optic nerve. At the time of diagnosis of intra-ocular retinoblastoma, three patients already had stage 4b disease; the other five patients developed metastatic disease at a median of 12 months (range
Two patients progressed prior to HCT and one patient died of toxicity during induction chemotherapy. Of the five patients that underwent HCT, two were event-free at 40 and 101 months. One of the event-free survivors received radiation therapy (external beam plus intrathecal radioimmunotherapy) and the other did not receive any form of radiation. Three patients had tumor recurrence at 3, 7, and 10 months post-HCT. The authors concluded that HCT may be beneficial for some patients with stage 4b retinoblastoma, but that longer follow-up is necessary to determine whether it is curative in this population.

PRACTICE GUIDELINE SUMMARY

AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

In 2015, the American Society for Blood and Marrow Transplantation (ASBMT) published consensus guidelines for clinically appropriate indications for hematopoietic cell transplantation (HCT) based on best prevailing evidence. The following was excerpted from original publication.[56] Indications for HCT in pediatric patients with the solid tumors types addressed in this review are outlined in Table 1.

Table 1. ASBMT Indications for HCT in Pediatric Patients with Solid Tumors[56]

<table>
<thead>
<tr>
<th>Indication and Disease Status</th>
<th>Allogeneic HCT*</th>
<th>Autologous HCT*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ewing sarcoma, high risk or relapse</td>
<td>D</td>
<td>S</td>
</tr>
<tr>
<td>Soft tissue sarcoma, high risk or relapse</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Neuroblastoma, high risk or relapse</td>
<td>D</td>
<td>S</td>
</tr>
<tr>
<td>Wilms tumor, relapse</td>
<td>N</td>
<td>C</td>
</tr>
<tr>
<td>Osteosarcoma, high risk</td>
<td>N</td>
<td>C</td>
</tr>
</tbody>
</table>

ASBMT: American Society for Blood and Marrow Transplantation; HCT: hematopoietic cell transplantation.

*“Standard of care (S): This category includes indications that are well defined and are generally supported by evidence in the form of high quality clinical trials and/or observational studies (eg, through CIBMTR or EBMT).”

“Standard of care, clinical evidence available (C): This category includes indications for which large clinical trials and observational studies are not available. However, HCT has been shown to be an effective therapy with acceptable risk of morbidity and mortality in sufficiently large single- or multi-center cohort studies. HCT can be considered as a treatment option for individual patients after careful evaluation of risks and benefits. As more evidence becomes available, some indications may be reclassified as ‘Standard of Care’.”

“Developmental (D): Developmental indications include diseases where pre-clinical and/or early phase clinical studies show HCT to be a promising treatment option. HCT is best pursued for these indications as part of a clinical trial. As more evidence becomes available, some indications may be reclassified as ‘Standard of Care, Clinical Evidence Available’ or ‘Standard of Care’.”

“Not generally recommended (N): Transplantation is not currently recommended for these indications where evidence and clinical practice do not support the routine use of HCT. The effectiveness of non-transplant therapies for an earlier phase of a disease does not justify the risks of HCT. Alternatively, a meaningful benefit is not expected from the procedure in patients with an advanced phase of a disease. However, this recommendation does not preclude investigation of HCT as a potential treatment and transplantation may be pursued for these indications within the context of a clinical trial.”

NATIONAL COMPREHENSIVE CANCER NETWORK

For Ewing sarcoma, the National Comprehensive Cancer Network (NCCN) guidelines for bone cancer (v.1.2019) state the following:[57]

“High dose chemotherapy followed by stem cell transplant (HDT/SCT) has been evaluated in patients with localized as well as metastatic disease. HDT/SCT has been associated with potential survival benefit in patients with non-metastatic disease. However, studies that have
evaluated HDT/SCT in patients with primary metastatic disease have shown conflicting results…. HDT/SCT has been associated with improved long-term survival in patients with relapsed or progressive Ewing sarcoma in small, single-institution studies. The role of this approach is yet to be determined in prospective randomized studies."

### SUMMARY

#### NEUROBLASTOMA

**Single Autologous Hematopoietic Cell Transplantation**

There is enough research to show improved event-free survival (EFS) and overall survival (OS) with use of single autologous hematopoietic cell transplantation (HCT) for treatment of children with high-risk neuroblastoma. Therefore, use of single autologous HCT may be considered medically necessary for first-line treatment of high-risk neuroblastoma, or as treatment of recurrent or refractory neuroblastoma.

**Tandem Autologous Hematopoietic Cell Transplantation**

No studies directly comparing single autologous to tandem autologous hematopoietic cell transplantation (HCT) for high-risk neuroblastoma have been published; however, case series on the use of tandem autologous for high-risk neuroblastoma have reported event-free survival (EFS) rates superior to those reported with the use of single autologous HCT (reported in randomized trials comparing single autologous HCT with conventional chemotherapy). Therefore, among pediatric patients with high-risk neuroblastoma, treatment with tandem HCT may be considered medically necessary.

**Allogeneic Hematopoietic Cell Transplantation**

Evidence of the use of allogeneic HCT for high-risk neuroblastoma does not show a survival benefit over autologous HCT, and is also associated with a higher risk of transplant-related mortality. Given there are no studies demonstrating treatment benefit with allogeneic HCT, the use of this intervention is considered investigational.

#### EWING’S SARCOMA FAMILY OF TUMORS

There is not enough research to show that autologous hematopoietic cell transplantation (HCT) is beneficial in the initial treatment of high-risk or recurrent or refractory Ewing’s sarcoma family of tumors (ESFT). Therefore, use of autologous HCT in ESFT is considered investigational.

It appears that the use of allogeneic hematopoietic cell transplantation may improve overall health outcomes when used to consolidate remissions or treat residual, recurrent or refractory Ewing’s sarcoma. Therefore, allogeneic HCT may be considered medically necessary in this population.

#### RHABDOMYOSARCOMA

There is not enough research to show that hematopoietic cell transplantation (HCT) improves overall health outcomes for those with metastatic rhabdomyosarcoma (RMS).
Therefore, use of autologous or allogeneic cell transplant in RMS is considered investigational.

**WILMS TUMOR**

The use of hematopoietic cell transplantation (HCT) has not consistently shown an overall health benefit in all patients with high-risk relapsed Wilms tumors, though few reports have suggested some benefit in certain subpopulations (e.g., patients with advanced-stage disease with lung-only metastases). Additional trials are needed to establish which patients might benefit from HCT treatment. There is enough research to show that there is a potential benefit in some high-risk, relapsed Wilms tumor patients; therefore use of autologous HCT in this population may be considered medically necessary. Autologous HCT for non high-risk, relapsed Wilms tumor patients, and allogeneic HCT in all Wilms tumor patients is considered investigational.

**OSTEOSARCOMA**

There is not enough research to show that autologous or allogeneic hematopoietic cell transplantation (HCT) for osteosarcoma improves overall health outcomes, such as overall survival. Therefore, the use of HCT in osteosarcoma is considered investigational.

**RETINOBLASTOMA**

**Localized Retinoblastoma**

There is not enough research to know if or how well autologous or allogeneic hematopoietic cell transplantation (HCT) works to treat patients with localized retinoblastoma. This does not mean it doesn’t work, but more research is needed to know for sure. Therefore, the use of autologous or allogeneic HCT in retinoblastoma is considered investigational.

**Metastatic Retinoblastoma**

It appears that autologous hematopoietic cell transplantation (HCT) may improve overall health outcomes for some people with metastatic retinoblastoma. Therefore use of autologous HCT in this population may be considered medically necessary.

**REFERENCES**


## CODES

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204</td>
<td>Management of recipient hematopoietic cell donor search and cell acquisition</td>
</tr>
<tr>
<td></td>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic; autologous</td>
</tr>
<tr>
<td></td>
<td>38206</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td></td>
<td>38207</td>
<td></td>
</tr>
</tbody>
</table>

---

TRA45.37 | 21
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38208</td>
<td>Thawing of previously frozen harvest, without washing, per donor</td>
</tr>
<tr>
<td>38209</td>
<td>Thawing of previously frozen harvest with washing, per donor</td>
</tr>
<tr>
<td>38210</td>
<td>Specific cell depletion with harvest, T cell depletion</td>
</tr>
<tr>
<td>38211</td>
<td>Tumor cell depletion</td>
</tr>
<tr>
<td>38212</td>
<td>Red blood cell removal</td>
</tr>
<tr>
<td>38213</td>
<td>Platelet depletion</td>
</tr>
<tr>
<td>38214</td>
<td>Plasma (volume) depletion</td>
</tr>
<tr>
<td>38215</td>
<td>Cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
<tr>
<td>38220</td>
<td>Diagnostic bone marrow; aspiration(s)</td>
</tr>
<tr>
<td>38221</td>
<td>Diagnostic bone marrow; biopsy(ies)</td>
</tr>
<tr>
<td>38222</td>
<td>Diagnostic bone marrow; biopsy(ies) and aspiration(s)</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Autologous transplantation</td>
</tr>
<tr>
<td>38243</td>
<td>HPC boost</td>
</tr>
<tr>
<td>38242</td>
<td>Allogeneic lymphocyte infusions</td>
</tr>
</tbody>
</table>

**APPENDIX I: Glossary of Terms Used in this Policy**

**consolidation therapy**[^1] - Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.

**relapse**[^2] - The return of a disease or the signs and symptoms of a disease after a period of improvement.

**salvage therapy**[^3] - Treatment that is given after the cancer has not responded to other treatments.

**tandem transplant**[^4] – Refers to a planned second course of high-dose therapy and HCT within six months of the first course.

---


4. NCCN Guidelines Version 2.2018 Multiple Myeloma |

Date of Origin: May 2010